The expression of potency of neutralizing antibodies for interferons and other cytokines.

S E Grossberg, Y Kawade
{"title":"The expression of potency of neutralizing antibodies for interferons and other cytokines.","authors":"S E Grossberg,&nbsp;Y Kawade","doi":"10.1007/BF02678220","DOIUrl":null,"url":null,"abstract":"<p><p>The occurrence of antibody formation in patients administered biologically active human proteins as biotherapy for different diseases emphasizes the importance of establishing a common method of reporting neutralizing antibody levels for such cytokines. For quantitative neutralization bioassays, the preferred expression of the neutralizing potency of an antiserum is a titer, that is, the dilution of serum that reduces 10 Laboratory Units (LU)/ml of the cytokine to 1 Laboratory Unit/ml, the endpoint of most bioassays. This 10-to-1 LU/ml expression, which has been recommended by the World Health Organization for recording the results of interferon neutralization by the constant interferon method (with varying dilutions of serum) can also be used with the constant antibody method (with varying concentrations of interferon). For various reasons, interferon doses in International Units (IU)/ml should not be used for the neutralization test. Should the interferon concentration vary, intentionally or otherwise, from the intended dose of 10 LU/ml, a simple calculation allows expression of the neutralizing potency as the recommended reduction of 10-to-1 LU/ml as follows: the titer to be reported is the reciprocal of the antibody dilution (achieving the endpoint), multiplied by the interferon concentration (measured in that day's titration) minus one, divided by 9. This index of neutralization is the preferred method to represent the neutralizing potency of polyclonal and monoclonal antibodies and should make the results from different laboratories more readily interpretable and enable comparison.</p>","PeriodicalId":77043,"journal":{"name":"Biotherapy (Dordrecht, Netherlands)","volume":"10 1","pages":"93-8"},"PeriodicalIF":0.0000,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02678220","citationCount":"34","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotherapy (Dordrecht, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02678220","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 34

Abstract

The occurrence of antibody formation in patients administered biologically active human proteins as biotherapy for different diseases emphasizes the importance of establishing a common method of reporting neutralizing antibody levels for such cytokines. For quantitative neutralization bioassays, the preferred expression of the neutralizing potency of an antiserum is a titer, that is, the dilution of serum that reduces 10 Laboratory Units (LU)/ml of the cytokine to 1 Laboratory Unit/ml, the endpoint of most bioassays. This 10-to-1 LU/ml expression, which has been recommended by the World Health Organization for recording the results of interferon neutralization by the constant interferon method (with varying dilutions of serum) can also be used with the constant antibody method (with varying concentrations of interferon). For various reasons, interferon doses in International Units (IU)/ml should not be used for the neutralization test. Should the interferon concentration vary, intentionally or otherwise, from the intended dose of 10 LU/ml, a simple calculation allows expression of the neutralizing potency as the recommended reduction of 10-to-1 LU/ml as follows: the titer to be reported is the reciprocal of the antibody dilution (achieving the endpoint), multiplied by the interferon concentration (measured in that day's titration) minus one, divided by 9. This index of neutralization is the preferred method to represent the neutralizing potency of polyclonal and monoclonal antibodies and should make the results from different laboratories more readily interpretable and enable comparison.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
干扰素和其他细胞因子的中和抗体效力的表达。
在不同疾病的生物治疗中使用生物活性人类蛋白的患者中抗体形成的发生,强调了建立一种报告此类细胞因子中和抗体水平的通用方法的重要性。对于定量中和性生物测定,抗血清中和效力的首选表达是效价,也就是说,将10个实验室单位(LU)/ml的细胞因子稀释到1个实验室单位/ml,这是大多数生物测定的终点。这种10比1 LU/ml的表达,已被世界卫生组织推荐用于记录用恒定干扰素法(使用不同稀释度的血清)进行干扰素中和的结果,也可用于恒定抗体法(使用不同浓度的干扰素)。由于各种原因,干扰素剂量在国际单位(IU)/ml不应用于中和试验。如果干扰素浓度有意或无意地偏离10 LU/ml的预期剂量,则可以通过简单的计算将中和效价表示为推荐的10比1 LU/ml的减少量,如下所示:要报告的效价是抗体稀释度(达到终点)的倒数乘以干扰素浓度(在当天的滴定中测量)减去1,除以9。这种中和指数是表示多克隆和单克隆抗体中和效力的首选方法,应该使不同实验室的结果更容易解释和比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Regulatory T Cells Mammalian target of rapamycin(mTOR)阻害薬 Oral administration of HSP-containing E. coli extract OM-89 has suppressive effects in autoimmunity. Regulation of autoimmune processes by modulating peripheral immunity towards hsp's? Heat shock proteins and the antitumor T cell response. Antigen-specific therapies in multiple sclerosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1